From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilson Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Meghan E. Shea, MD, attending medical oncologist, ambulatory medical director, disease program leader for medical oncology, Beth Israel Deaconess Medical Center

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

ByUrsula A. Matulonis, MD,Meghan E. Shea, MD

May 27th 2026

Drs Matulonis and Shea explore the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and ADCs across disease settings.

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Elizabeth H. Stover, MD, PhD, physician, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School

RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD

ByUrsula A. Matulonis, MD,Elizabeth H. Stover, MD, PhD

April 24th 2026

Drs Matulonis and Stover explore the biology and therapeutic relevance of the RAS/MAP kinase pathway in gynecologic cancers.

The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

ByUrsula A. Matulonis, MD,Katharine M. Esselen, MD, MBA

March 31st 2026

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

ByUrsula A. Matulonis, MD,Susana M. Campos, MD, MPH

February 25th 2026

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

ByUrsula A. Matulonis, MD,Rebecca L. Porter, MD, PhD

January 28th 2026

Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

ByUrsula A. Matulonis, MD,Panagiotis A. Konstantinopoulos, MD, PhD

December 11th 2025

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

ByUrsula A. Matulonis, MD,Taymaa May, MD, MSc

November 13th 2025

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD

The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA

Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

Immuno-Oncology and Novel Cell Therapies Set Transformation in Motion for Gynecologic Oncology: With Ursula A. Matulonis, MD; and Rebecca Porter, MD, PhD

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

Trending on OncLive

Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings

Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026

Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer

Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL

FDA Grants Priority Review to Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer